Valdecoxib
SIGMA/PZ0179 - ≥98% (HPLC)
Synonym: 4-
CAS Number: 181695-72-7
Empirical Formula (Hill Notation): C16H14N2O3S
Molecular Weight: 314.36
MDL Number: MFCD00950568
Linear Formula: C16H14N2O3S
Product Type: Chemical
| assay | ≥98% (HPLC) |
| color | white to off-white |
| form | powder |
| InChI | 1S/C16H14N2O3S/c1-11-15(1 |
| InChI key | LNPDTQAFDNKSHK-UHFFFAOYSA |
| Quality Level | 100 ![]() |
| SMILES string | Cc1onc(-c2ccccc2)c1-c3ccc |
| solubility | DMSO: >25 mg/mL |
| storage temp. | room temp |
| Application: | Valdecoxib may be used: as cyclooxygenase-2 (COX-2) inhibitor in fibroblast cells, as an analyte for mass spectrometry analysis, as an standard in ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) for quantification of valdecoxib in plasma samples |
| Biochem/physiol Actions: | Valdecoxib is a non-steroidal anti-inflammatory drug (NSAID), a cyclooxygenase-2 (COX-2) selective inhibitor. |
| Biochem/physiol Actions: | Valdecoxib is reported to elicit anti-inflammatory, analgesic and antipyretic functionality. It acts as a substrate for the liver enzyme cytochrome P450 2C9(CYP2C9) and cytochrome P450 3A4 (CYP3A4). |
| General description: | Valdecoxib (VCX) is a diaryl substituted isoxazole compound. It comprises of sulfonyl propanamide and is a metabolite of parecoxib. |
| Packaging: | 5, 25 mg in glass bottle |
| Symbol | ![]() GHS08,GHS09 |
| Signal word | Warning |
| Hazard statements | H361d - H373 - H410 |
| Precautionary statements | P201 - P202 - P260 - P273 - P280 - P308 + P313 |
| Hazard Codes | Xn,N |
| Risk Statements | 63-48/22-51/53 |
| Safety Statements | 36/37-61 |
| RIDADR | NONH for all modes of transport |
| WGK Germany | WGK 3 |
| Flash Point(F) | Not applicable |
| Flash Point(C) | Not applicable |
| Purity | ≥98% (HPLC) |
| Storage Temp. | room temp |
| UNSPSC | 12352200 |



